Amanda Ricciuto, Kuan Liu, Wael El-Matary, Mansi Amin, Achiya Z Amir, Madeleine Aumar, Marcus Auth, Matthew D Di Guglielmo, Eleonora Druve Tavares Fagundes, Alexandre Rodrigues Ferreira, Katryn N Furuya, Nitika Gupta, Stephen Guthery, Simon P Horslen, Kyle Jensen, Binita M Kamath, Nanda Kerkar, B G P Koot, Trevor J Laborda, Christine K Lee, Kathleen M Loomes, Cara Mack, Mercedes Martinez, Aldo Montano-Loza, Nadia Ovchinsky, Alexandra Papadopoulou, Emily R Perito, Pushpa Sathya, Kathleen B Schwarz, Uzma Shah, Eyal Shteyer, Nisreen Soufi, James Patrick Stevens, Amy Taylor, M Elizabeth Tessier, Pamela Valentino, Marek Woynarowski, Mark Deneau
BACKGROUND: Data on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited. AIMS: Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity. METHODS: In this retrospective multi-centre cohort study, we matched vancomycin-treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin...
March 10, 2024: Alimentary Pharmacology & Therapeutics